评价外用吡美莫司治疗非特应性结节性痒疹的止痒效果：一项随机、氢化可的松对照、双盲 II 期试验的结果。
Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial.
机构信息
Competence Center Chronic Pruritus, Department of Dermatology, University Hospital of Münster, Münster, Germany.
出版信息
Dermatology. 2013;227(4):353-60. doi: 10.1159/000355671. Epub 2013 Nov 23.
BACKGROUND
In the treatment of atopic dermatitis, pimecrolimus has high antipruritic effects.
OBJECTIVE
To investigate the efficacy of 1% pimecrolimus cream in comparison to 1% hydrocortisone cream in non-atopic prurigo nodularis (PN).
METHODS
A randomized, controlled, double-blind study with intraindividual randomization was done in 30 patients (17 females, 13 males; mean age 58.5 years) with PN.
RESULTS
Pruritus intensity decreased significantly (p < 0.001) on both treated sides as early as after 10 days of treatment; scratch lesions improved (p < 0.001). Quality of life as assessed by the Dermatology Life Quality Index improved significantly. However, a significant advantage of pimecrolimus over hydrocortisone was not found.
CONCLUSION
The results suggest that the non-steroid pimecrolimus is an effective alternative for PN treatment.
背景
在特应性皮炎的治疗中，吡美莫司具有较高的止痒效果。
目的
研究 1%吡美莫司乳膏治疗非特应性结节性痒疹（PN）的疗效与 1%氢化可的松乳膏的疗效。
方法
对 30 例（17 名女性，13 名男性；平均年龄 58.5 岁）PN 患者进行了一项随机、对照、双盲、个体内随机研究。
结果
治疗 10 天后，双侧瘙痒强度均显著下降（p<0.001）；搔抓皮损明显改善（p<0.001）。皮肤病生活质量指数评估的生活质量显著改善。然而，并未发现吡美莫司明显优于氢化可的松。
结论
结果表明，非甾体类吡美莫司是治疗 PN 的有效替代药物。
Zotero 插件